[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100314848":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":21,"studyPopulation":22,"armGroups":17,"interventions":17,"overallOfficials":17,"centralContacts":23,"locations":29,"responsibleParty":168,"collaborators":17,"id":170,"slug":171,"hasResults":172,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":172,"sex":178,"minAge":179,"maxAge":17,"enrollmentInfo":180,"targetDuration":183,"studyType":184,"phases":17,"briefSummary":185,"conditions":186,"keywords":17,"overallStatus":32,"whyStopped":17,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":198},{"fullName":5,"class":6},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Accrual rates","Determine feasibility of achieving high accural rates (greater than 80%) with this approach.","2 years",[14],{"measure":15,"description":16,"timeFrame":12},"Number of cmRCT trials activated","Measure if success would be the activation of 2 or more trials in the time frame.",null,{"allocation":17,"interventionModel":17,"interventionModelDescription":17,"primaryPurpose":17,"observationalModel":19,"timePerspective":20,"maskingInfo":17},"COHORT","PROSPECTIVE","The study consists of an effort to develop infrastructure that will support systematic collection of data from daily radiotherapy practice. At the core, PERA is a large observational cohort study, serving as a multiple cohort randomized trial and image banking facility. It includes consent for the collection of imaging data, patient-reported outcomes, and broad randomization for studies according to the innovative cohort multiple randomized controlled trial design (cmRCT).\n\nThe basis of this design is a prospective cohort of participants receiving care as usual, who give informed consent for cohort participation.\n\nParticipants can furthermore be asked for informed consent to be randomized in future RCTs conducted within the cohort. Participants are informed that they will be offered an experimental intervention if they are randomly selected. They are also informed that they otherwise might serve as controls without being notified and that their data can be used in a trial context. For each participant in the cohort, PROs are captured at baseline and at regular intervals during follow-up. Within this cohort, multiple RCTs can be conducted. The design is especially attractive for clinical research areas with rapid evolution of technology, and for highly desired or expensive interventions.\n\nIn the first stage, at entry into the cohort, all potential participants are asked for their informed consent to participate in a cohort study and broad consent to be either randomly selected to be approached for experimental interventions or to serve as control without further notice during participation in the cohort. In a second stage, at the initiation of an RCT within the cohort, informed consent to receive the intervention is then only sought in those randomly selected for the intervention arm. At the third stage, after completion of each RCT, all cohort participants receive aggregate disclosure of trial results.","Patients receiving standard-care radiotherapy at CHUM",[24],{"name":25,"role":26,"phone":27,"phoneExt":17,"email":28},"Cynthia Ménard, MD, M.Sc","CONTACT","514-890-8254","Cynthia.Menard@umontreal.ca",[30,51,67,84,98,110,125,140,153],{"facility":31,"status":32,"city":33,"state":34,"zip":17,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"BC Cancer - Kelowna","RECRUITING","Kelowna","British Columbia","Canada","CA",{"type":38,"coordinates":39},"Point",[40,41],-119.48568,49.88307,{"lat":41,"lon":40},[44,48],{"name":45,"role":26,"phone":46,"phoneExt":17,"email":47},"Jennifer Petterson","Petterson","jennifer.petterson@bccancer.bc",{"name":49,"role":50,"phone":17,"phoneExt":17,"email":17},"Katie Jasper, MD","PRINCIPAL_INVESTIGATOR",{"facility":52,"status":32,"city":53,"state":34,"zip":54,"country":35,"countryCode":36,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"BC Cancer - Vancouver","Vancouver","V5Z 4E6",{"type":38,"coordinates":56},[57,58],-123.11934,49.24966,{"lat":58,"lon":57},[61,65],{"name":62,"role":26,"phone":63,"phoneExt":17,"email":64},"Jackie Cao","(250) 712-3900","sijia.cao@bccancer.bc.ca",{"name":66,"role":50,"phone":17,"phoneExt":17,"email":17},"Srinivas Raman, MD",{"facility":68,"status":32,"city":69,"state":70,"zip":71,"country":35,"countryCode":36,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"London Health Regional Cancer Centre","London","Ontario","N6C 2R5",{"type":38,"coordinates":73},[74,75],-81.23304,42.98339,{"lat":75,"lon":74},[78,82],{"name":79,"role":26,"phone":80,"phoneExt":17,"email":81},"Karen Eddy","(519) 685-8500","karen.eddy@lhsc.on.ca",{"name":83,"role":50,"phone":17,"phoneExt":17,"email":17},"Pencilla Lang, MD",{"facility":85,"status":32,"city":86,"state":70,"zip":87,"country":35,"countryCode":36,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Sunnybrook Research Institute","Toronto","M4N 3M5",{"type":38,"coordinates":89},[90,91],-79.39864,43.70643,{"lat":91,"lon":90},[94,96],{"name":17,"role":26,"phone":95,"phoneExt":17,"email":17},"514-934-1934",{"name":97,"role":50,"phone":17,"phoneExt":17,"email":17},"Amir Safavi, MD",{"facility":99,"status":32,"city":86,"state":70,"zip":17,"country":35,"countryCode":36,"cosmosGeoPoint":100,"geoPoint":102,"contacts":103},"Princess Margaret Cancer Centre",{"type":38,"coordinates":101},[90,91],{"lat":91,"lon":90},[104,108],{"name":105,"role":26,"phone":106,"phoneExt":17,"email":107},"Ebrahim Aslani","(416) 946-6560","ebrahim.aslani@uhn.ca",{"name":109,"role":50,"phone":17,"phoneExt":17,"email":17},"Philip Wong",{"facility":111,"status":32,"city":112,"state":113,"zip":17,"country":35,"countryCode":36,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"CISSS de Laval - Hôpital de la Cité-de-la-Santé","Laval","Quebec",{"type":38,"coordinates":115},[116,117],-73.692,45.56995,{"lat":117,"lon":116},[120,123],{"name":121,"role":26,"phone":17,"phoneExt":17,"email":122},"Imane Benmouhoub","imane.benmouhoub.cissslav@ssss.gouv.qc.ca",{"name":124,"role":50,"phone":17,"phoneExt":17,"email":17},"Danny Duplan, MD",{"facility":126,"status":32,"city":127,"state":113,"zip":128,"country":35,"countryCode":36,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Research Institute of the McGill University Health Center","Montreal","H3H 2R9",{"type":38,"coordinates":130},[131,132],-73.58781,45.50884,{"lat":132,"lon":131},[135,138],{"name":136,"role":26,"phone":95,"phoneExt":17,"email":137},"Marianna Perna","marianna.perna@muhc.mcgill.ca",{"name":139,"role":50,"phone":17,"phoneExt":17,"email":17},"Fabio Cury, MD",{"facility":141,"status":32,"city":127,"state":113,"zip":17,"country":35,"countryCode":36,"cosmosGeoPoint":142,"geoPoint":144,"contacts":145},"Centre Hospitalier de l'Université de Montréal",{"type":38,"coordinates":143},[131,132],{"lat":132,"lon":131},[146,151],{"name":147,"role":26,"phone":148,"phoneExt":149,"email":150},"Eva Nkurunziza","514-890-8000","30898","eva-sabrina.nkurunziza.chum@ssss.gouv.qc.ca",{"name":152,"role":50,"phone":17,"phoneExt":17,"email":17},"Cynthia Ménard, MD",{"facility":154,"status":32,"city":155,"state":113,"zip":17,"country":35,"countryCode":36,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"CHU de Québec - Université Laval","Québec",{"type":38,"coordinates":157},[158,159],-71.21454,46.81228,{"lat":159,"lon":158},[162,166],{"name":163,"role":26,"phone":164,"phoneExt":17,"email":165},"Alexandre Villeneuve-Gauthier","4185254444","Alexandre.Villeneuve-Gauthier@chudequebec.ca",{"name":167,"role":50,"phone":17,"phoneExt":17,"email":17},"Eric Vigneault, MD",{"type":169,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100314848","evaluation-of-technological-innovation-in-radiotherapy-100314848",false,"NCT03378856","Evaluation of Technological Innovation in Radiotherapy","Partnership Initiative for the Evaluation of Technological Innovation in Radiotherapy","PERA","Inclusion Criteria:\n\n* Ability to provide informed consent\n* Receiving radiotherapy or brachytherapy\n\nExclusion Criteria:\n\n\\-","ALL","18 Years",{"count":181,"type":182},1500,"ESTIMATED","5 Years","OBSERVATIONAL","Prospective cohort study of patients receiving standard-care radiotherapy is paramount to a better understanding of radiation effects and longterm outcomes.\n\nThe primary objective is to determine the feasibility of establishing infrastructure to systematically collect clinical data, patient-reported outcomes, and imaging data from daily radiotherapy practice.\n\nSecondary objectives are to provide a control cohort for comparative effectiveness research of investigational interventions through a cmRCT design; compare imaging features with clinical outcomes; understand dose-effect relationships; quantify imaging quality metrics.",[187,188],"Cancer","Radiotherapy Side Effect","2026-08-28",{"date":191,"type":192},"2026-09-01","ACTUAL",{"date":194,"type":192},"2017-11-01",{"date":196,"type":182},"2040-10",{"name":5,"class":6},9]